MyoKardia Readies First-Ever Hypertrophic Cardiomyopathy Drug For US Filing
Executive Summary
The Phase III EXPLORER-HCM trial evaluating mavacamten in obstructive hypertrophic cardiomyopathy (oHCM) succeeded on all primary and secondary endpoints.